Provided by Tiger Trade Technology Pte. Ltd.

Avalo Therapeutics Inc

19.27
-0.5600-2.82%
Post-market: 19.270.00000.00%19:30 EDT
Volume:759.04K
Turnover:14.70M
Market Cap:1.03B
PE:-4.37
High:19.86
Open:19.86
Low:18.88
Close:19.83
52wk High:24.27
52wk Low:8.65
Shares:53.63M
Float Shares:40.15M
Volume Ratio:0.95
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4100
EPS(LYR):-5.8400
ROE:-36.27%
ROA:-18.50%
PB:2.30
PE(LYR):-3.30

Loading ...

Avalo Therapeutics Shares Jump 43.5% Premarket After Co's Skin Disease Drug Meets Mid-Stage Trial Goal

THOMSON REUTERS
·
May 06

Julian Harrison Raises AVTX Price Target to $58 on Strong Phase 2 LOTUS Data and Differentiated Safety Profile for Abdakibart

TIPRANKS
·
May 06

U.S. RESEARCH ROUNDUP-IBM, Lumentum Holdings, TransDigm Group

Reuters
·
May 06

Avalo Therapeutics prices USD 375 million follow-on offering at USD 17.75/share

Reuters
·
May 06

Avalo Therapeutics Inc - Shares Sold at $17.75 per Share

THOMSON REUTERS
·
May 06

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

THOMSON REUTERS
·
May 06

Avalo Therapeutics announces common stock and warrants offering, no amount given

TIPRANKS
·
May 06

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire
·
May 06

Avalo reports Phase 2 LOTUS trial meets primary endpoint for HS drug abdakibart

Reuters
·
May 06

Avalo Therapeutics Inc - Reports Statistically Significant Benefit on Key Secondary Endpoints in Phase 2 Lotus Trial

THOMSON REUTERS
·
May 06

Avalo Therapeutics Inc - Phase 2 Lotus Trial Meets Primary Endpoint With 42.2% and 42.9% Response Rates at Week 16

THOMSON REUTERS
·
May 06

Avalo Therapeutics Inc - Abdakibart Well Tolerated With Favorable Safety Profile in Phase 2 Lotus Trial

THOMSON REUTERS
·
May 06

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

GlobeNewswire
·
May 06

Avalo CFO Christopher Sullivan disposes of $221,466 in common shares

Reuters
·
May 02

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 30

BRIEF-Avalo Therapeutics Enters Milestone Buyout Option Agreement On April 26 - SEC Filing

Reuters
·
Apr 28

Avalo Therapeutics Inc - Avalo Has Agreed to Pay $2.25 Mln to Former Almatabio Securityholders for an Option

THOMSON REUTERS
·
Apr 28

Avalo Therapeutics Inc - to Pay $2.25 Mln to Securityholders' Representative Within Five Business Days of April 26, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 28

Avalo Therapeutics Inc - Enters Milestone Buyout Option Agreement on April 26, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 28

Avalo buys option to cut AlmataBio milestone payment to $5.13 million

Reuters
·
Apr 28